Does Rallies show 13F holders for PGNY?

Yes. Rallies tracks hedge fund and 13F ownership data for PGNY, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PGNY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PGNY. It does not provide personalized investment advice.

PGNY (Progyny, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Progyny, Inc. Common Stock (PGNY) is a publicly traded Healthcare sector company. As of May 21, 2026, PGNY trades at $25.61 with a market cap of $1.88B and a P/E ratio of 37.40. PGNY moved +4.35% today. Year to date, PGNY is -3.83%; over the trailing twelve months it is +17.24%. Its 52-week range spans $13.39 to $28.75. Analyst consensus is strong buy with an average price target of $27.75. Rallies surfaces PGNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PGNY stock?

Hedge funds tracked by Rallies that own PGNY include Centerbook Partners, Redmile Group, Duquesne Family, Orbimed Advisors, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Progyny, Inc. Common Stock.

PGNY Key Metrics

Key financial metrics for PGNY
Metric	Value
Price	$25.61
Market Cap	$1.88B
P/E Ratio	37.40
EPS	$0.68
Dividend Yield	0.00%
52-Week High	$28.75
52-Week Low	$13.39
Volume	1.78M
Avg Volume	0
Revenue (TTM)	$1.29B
Net Income	$58.52M
Gross Margin	23.63%

Top Hedge Funds Holding PGNY

Centerbook Partners holds 877.58K shares of PGNY, changed +51.79% as of Mar 31, 2026.
Redmile Group holds 320.86K shares of PGNY, changed +0.00% as of Mar 31, 2024.
Duquesne Family holds 295.12K shares of PGNY, changed +0.00% as of Dec 31, 2025.
Orbimed Advisors holds 259.90K shares of PGNY, changed +129.39% as of Jun 30, 2024.
Bridgewater Associates holds 65.64K shares of PGNY, changed +0.00% as of Sep 30, 2025.

Latest PGNY News

Barclays Raises Progyny Price Target to $27 After Q1 EPS Beat — May 15, 2026
Progyny Q1 Fertility Benefits Revenue Up 24% with $75M Buyback — May 8, 2026
Progyny Delivers Record Q1 Revenue of $328.5M, Gross Margin Hits 25.3% — May 7, 2026
Progyny sees Q1 revenue of $326.5M, EPS $0.26 with 12-month $27.55 target — May 6, 2026
Progyny Launches Fully Insured Fertility Plan with Fixed PEPM for Small Employers — Apr 16, 2026

Recent PGNY Insider Trades

Swartz Allison sold 599 (~$10.51K) on Mar 4, 2026.
Swartz Allison sold 500 (~$8.70K) on Mar 3, 2026.
Swartz Allison sold 4.16K (~$72.33K) on Mar 3, 2026.

PGNY Analyst Consensus

9 analysts cover PGNY: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.75.

Common questions about PGNY

Who owns PGNY stock?: Hedge funds tracked by Rallies that own PGNY include Centerbook Partners, Redmile Group, Duquesne Family, Orbimed Advisors, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Progyny, Inc. Common Stock.
Does Rallies show 13F holders for PGNY?: Yes. Rallies tracks hedge fund and 13F ownership data for PGNY, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PGNY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PGNY. It does not provide personalized investment advice.